Scope and limitations on aerosol drug delivery for the treatment of infectious respiratory diseases

• Published in: Journal of controlled release 2020-09, Vol.325, p.276-292
• Main Authors: Douafer, Hana, Andrieu, Véronique, Brunel, Jean Michel
• Format: Article
• Language: English
• Subjects: aerosol drug delivery; antibiotics; bacterial infections; Human health and pathology; Infectious diseases; infectious respiratory diseases; Life Sciences
• ISSN: 0168-3659; 1873-4995
• DOI: 10.1016/j.jconrel.2020.07.002

The rise of antimicrobial resistance has created an urgent need for the development of new methods for antibiotics delivery to patients with pulmonary infections in order to mainly increase the effectiveness of the drugs administration, to minimize the risk of emergence of resistant strains, and to prevent patients reinfection. Since bacterial resistance is often related to antibiotic concentration, their pulmonary administration could eradicate strains resistant to the same drug at the concentration achieved through the systemic circulation. Pulmonary administration offers several advantages; it directly targets the site of the infection which allows the inhaled dose of the drug to be reduced compared to that administered orally or parenterally while keeping the same local effect. The review article is made with an objective to compile information about various existing modern technologies developed to provide greater patient compliance and reduce the undesirable side effect of the drugs. In conclusion, aerosol antibiotic delivery appears as one of the best technologies for the treatment of pulmonary infectious diseases and able to limit the systemic adverse effects related to the high drug dose and to make life easier for the patients. [Display omitted]